Qilu Pharma In-licenses Bladder Cancer Drug in $35 Million Deal

Qilu Pharma of Jinan in-licensed Greater China rights to a treatment for bladder cancer from Seseen Bio of the US in a $35 million agreement. Qilu will also have global manufacturing rights to Vicineum, a proposed treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Qilu will make an upfront payment of $12 million and be responsible for up to $23 million in technology transfer and milestone payments, plus royalties. Vicineum is a locally administered fusion protein that has completed a Phase III trial for NMIBC. More details.... Share this with colleagues: // //